TUCSON, Arizona, August 24, 2026, 13:10 EDT
- Shares of Picard Medical rose 50.2% to $4.82 as of 12:45 p.m. EDT.
- Revenue increased by 39% in the second quarter, and gross margin stood at 20.9%.
- June cash was sufficient to cover about one day of operating cash outflow in the first half.
Picard Medical, Inc. NYSEAMERICAN:PMI surged 50.2% to $4.82 on Monday. By 12:45 p.m. EDT, 17.5 million shares had changed hands. The rally came after investors revisited the quarterly expansion of its SynCardia artificial-heart division.
The increase in revenue is genuine. However, the balance sheet leaves the rally on shaky ground. Picard finished June holding just $38,000 in cash and restricted cash.
This amount is roughly equivalent to 1.3 days of operating cash outflows for the first half. The figure is calculated by dividing $38,000 by Picard’s average daily operating cash usage. Over a six-month period, the company expended $5.15 million.
| Q2 measure | 2026 | 2025 | Change |
|---|---|---|---|
| Revenue | $2.95 million | $2.13 million | up 38.6% |
| Gross profit | $0.62 million | -$0.13 million | swung to positive |
| Gross margin | 20.9% | -6.0% | increase of 26.9 points |
| Operating loss | -$4.63 million | -$3.52 million | loss widened by 31.5% |
| Net loss | -$5.66 million | -$6.72 million | loss narrowed by 15.8% |
Quarterly results were propelled by product sales. Revenue increased to $2.95 million compared to $2.13 million a year earlier. Gross profit moved to $616,000, reversing a prior loss of $127,000. Interim Chief Executive Richard Fang said the revenue and gross profit increases reflect advances in the core business.
However, expenses climbed more rapidly. Research costs surged 85% to reach $1.37 million. Selling, general and administrative costs grew 46% to $3.87 million. Stock compensation made up all of the $1.2 million SG&A rise for the quarter.
| Capital test | Filed or calculated value | Investor reading |
|---|---|---|
| Cash and restricted cash as of June 30 | $38,000 | Significant cash need |
| Operating cash used in H1 | $5.15 million | Roughly $28,500 per day |
| Shares on issue, August 17 | 2.34 million | Adjusted for stock split |
| Equity value based on $4.82 share price | $11.27 million | Reuters calculation |
| Q2 net loss over implied equity value | 50.2% | Loss remains significant |
Trading volume on Monday reached about 22 times the 741,000-share average reported in Picard’s August investor presentation. This figure also far surpassed Friday’s turnover of 4.47 million shares. Shares traded within an intraday range between $3.97 and $5.35.
The market capitalization is still small. Based on 2.34 million shares, a price of $4.82 gives a value of $11.27 million. Picard reported a quarterly net loss of $5.66 million, which is nearly half of that market value.
Debt dropped significantly over the half, as Picard cut the senior secured note principal to $1.4 million from $15 million. Cash and shares were used to achieve this reduction. A May offering brought in $3.06 million net, but outstanding warrants mean potential for further dilution.
| Analyst recommendations | Coverage | Consensus | Average target |
|---|---|---|---|
| Picard Medical NYSEAMERICAN:PMI | No consensus from tracked analysts | Not disclosed | Not disclosed |
| Abbott Laboratories NYSE:ABT | 27 analysts | Buy | $119.40 |
| Medtronic plc NYSE:MDT | 29 analysts | Buy | $98.44 |
Coverage also sets the companies apart. Picard lacks a standard analyst consensus. In contrast, Abbott Laboratories NYSE:ABT and Medtronic plc NYSE:MDT receive wide attention from research analysts. Investors in Picard depend more on company filings and the details of financing agreements.
Concentration increases volatility. A single client accounted for 81% of revenue in the first half and made up 92% of receivables in June. Any change in this customer’s buying could outweigh limited sales growth.
The product stands out in the market. SynCardia reports over 2,100 total artificial heart implants in 27 countries. Picard is advancing work on the fully implantable Emperor platform as well. Both initiatives need funding before revenue expansion is possible.
Risks: Picard warned there is significant uncertainty regarding its ability to remain a going concern. Additional equity financing could dilute existing shareholders. If the company cannot secure funding, it may postpone product development or commercialization. Risks are heightened by customer concentration, listing compliance issues and volatility from a limited public float.
Monday’s surge reflects the improvement in gross margins. The upcoming challenge is securing financing. A single robust quarter will not resolve Picard’s cash shortfall without new funding.
Related articles: Earnings
